COSOPT-S® Treatment Versus Acetazolamide Before Trabeculectomy

Launched by KATRIN LORENZ · Oct 25, 2010

Keywords

ClinConnect Summary

The most common cause of post-trabeculectomy filtration failure is postoperative scarring. Long-term preoperative treatment with local antiglaucoma agents containing preservatives has an increased risk of post-operative scarring of the filtration bleb. Therefore many surgeons prepare their patients for planned trabeculectomy by discontinuing local antiglaucoma drugs, controlling IOP with oral acetazolamide, and treating the eye with local steroids.

Preservative-free COSOPT-S® eye drops b.i.d now provide a possibility to reduce IOP preoperatively with the aim of avoiding postoperative exces...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Male or female patients aged 18 years or older
• • Caucasian
• • A clinical diagnosis of open angle glaucoma, pseudoexfoliation or pigment dispersion glaucoma, or ocular hypertension in one or both eyes
• • Planned trabeculectomy
• • Previous treatment with antiglaucoma agents containing preservatives for at least one month
• • Best corrected visual acuity of 20/800 or better in the study eye
• Exclusion Criteria:
• • Secondary glaucoma except pseudoexfoliation glaucoma and pigmentary glaucoma
• • Current ocular infection, i.e. conjunctivitis or keratitis
• • Any abnormality preventing reliable applanation tonometry
• • Intraocular surgery or laser treatment within the past three months
• • History of surgery involving the conjunctiva
• • History of cataract surgery with sclerocorneal approach
• • Subject is allergic to sulfonamides
• • Reactive airway disease, including bronchial asthma or a history of bronchial asthma, or severe chronic obstructive pulmonary disease
• • Sinus bradycardia, second or third degree atrioventricular block, overt cardiac failure, cardiogenic shock
• • Severe renal dysfunction (CrCl \< 30 ml/min) or hyperchloraemic acidosis
• • Depressed blood levels of sodium and / or potassium
• • Marked kidney and liver disease or dysfunction, gout, suprarenal gland failure, hypercalciuria or nephrocalcinosis
• • History of hypersensitivity to the investigational medicinal products or to any drug